An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

Stopped Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.

Conditions

• Crohn's Disease
• IBD

Interventions

• DRUG: Brazikumab low dose
• DRUG: Brazikumab high dose
• DRUG: Humira®
• DRUG: Placebo

Sponsor

AstraZeneca